中文

Deals

AstraZeneca and Bristol-Myers Squibb's 'mega-merger' rumors raise Wall Street concerns

The Financial Times, citing sources familiar with the matter, reported that AstraZeneca and Bristol-Myers Squibb discussed a merger in recent months, but Wall Street reacted negatively, with AstraZeneca's share price falling over 8% at one point, erasing approximately $22 billion in market value. Analysts questioned the rationale for the deal and noted that antitrust issues and valuation differences could be major obstacles.

Deals

Our partners